| Literature DB >> 33488920 |
Ryan Rivera-Oyola1,2,3,4,5,6,7,8,9,10, Roselyn Stanger1,2,3,4,5,6,7,8,9,10, Graham H Litchman1,2,3,4,5,6,7,8,9,10, Quinn Thibodeaux1,2,3,4,5,6,7,8,9,10, John Koo1,2,3,4,5,6,7,8,9,10, Richard Fried1,2,3,4,5,6,7,8,9,10, Gary Goldenberg1,2,3,4,5,6,7,8,9,10, George Han1,2,3,4,5,6,7,8,9,10, Sylvia Hsu1,2,3,4,5,6,7,8,9,10, Leon Kircik1,2,3,4,5,6,7,8,9,10, Melissa Knuckles1,2,3,4,5,6,7,8,9,10, Andrea Murina1,2,3,4,5,6,7,8,9,10, Jeffrey Weinberg1,2,3,4,5,6,7,8,9,10, Jashin J Wu1,2,3,4,5,6,7,8,9,10, Mark Lebwohl1,2,3,4,5,6,7,8,9,10.
Abstract
Brodalumab, a first-in-class interleukin-17 (IL-17) receptor blocker, carries a black box warning for suicidal ideation and behavior, yet it is also one of the most powerful biologic agents in our armamentarium. We wish to highlight three patients with moderate-to-severe psoriasis and comorbid depression who were successfully treated with brodalumab. The patients were chosen by an expert panel comprising dermatologists, psychiatrists, and psychologists. Psoriasis disease severity was measured using the Psoriasis Area and Severity Index (PASI) score. All three patients experienced PASI 100 after treatment with brodalumab (N=3). Importantly, depressive symptoms improved or resolved in two out of three patients. One patient, who had a history of psychiatric hospitalizations, required in-patient psychiatric treatment during treatment. The use of brodalumab in patients with psoriasis can provide rapid-onset improvement in both skin and depressive symptoms.Entities:
Keywords: Psoriasis; brodalumab; depression; suicidality
Year: 2020 PMID： 33488920 PMCID： PMC7819587
Source DB: PubMed Journal: J Clin Aesthet Dermatol ISSN： 1941-2789